Brokerages predict that Avrobio Inc (NASDAQ:AVRO) will report earnings per share of ($0.76) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Avrobio’s earnings. The highest EPS estimate is ($0.70) and the lowest is ($0.78). Avrobio reported earnings per share of ($2.98) in the same quarter last year, which would suggest a positive year-over-year growth rate of 74.5%. The firm is expected to announce its next quarterly earnings results on Thursday, August 8th.
According to Zacks, analysts expect that Avrobio will report full-year earnings of ($2.93) per share for the current financial year, with EPS estimates ranging from ($3.12) to ($2.54). For the next year, analysts forecast that the business will report earnings of ($3.07) per share, with EPS estimates ranging from ($3.45) to ($2.65). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Avrobio.
Avrobio (NASDAQ:AVRO) last released its earnings results on Monday, May 13th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.01).
Several analysts recently issued reports on AVRO shares. Cowen reiterated a “buy” rating on shares of Avrobio in a report on Monday. Mizuho assumed coverage on Avrobio in a research note on Wednesday, June 26th. They issued a “buy” rating and a $28.00 price objective on the stock. Janney Montgomery Scott assumed coverage on Amicus Therapeutics in a research note on Friday, April 5th. They issued a “buy” rating and a $13.91 price objective on the stock. HC Wainwright set a $25.00 price objective on Onconova Therapeutics and gave the company a “buy” rating in a research note on Tuesday, May 14th. Finally, Zacks Investment Research upgraded Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Tuesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $27.90.
AVRO traded up $0.47 on Friday, hitting $23.37. 17,861 shares of the company were exchanged, compared to its average volume of 211,280. Avrobio has a 12 month low of $11.85 and a 12 month high of $53.70. The company has a market cap of $462.66 million and a P/E ratio of -6.33. The company has a fifty day moving average price of $14.99.
Large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp raised its stake in Avrobio by 60.6% in the fourth quarter. Bank of New York Mellon Corp now owns 25,937 shares of the company’s stock valued at $431,000 after buying an additional 9,782 shares during the period. Rhumbline Advisers bought a new position in shares of Avrobio during the first quarter worth approximately $296,000. Aisling Capital Management LP increased its stake in shares of Avrobio by 10.2% during the first quarter. Aisling Capital Management LP now owns 811,998 shares of the company’s stock worth $17,905,000 after purchasing an additional 75,000 shares during the period. Emerald Advisers LLC increased its stake in shares of Avrobio by 61.4% during the first quarter. Emerald Advisers LLC now owns 614,408 shares of the company’s stock worth $13,548,000 after purchasing an additional 233,772 shares during the period. Finally, BlackRock Inc. increased its stake in shares of Avrobio by 73.4% during the fourth quarter. BlackRock Inc. now owns 651,959 shares of the company’s stock worth $10,854,000 after purchasing an additional 276,018 shares during the period. Hedge funds and other institutional investors own 71.13% of the company’s stock.
Avrobio Company Profile
AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.
Featured Story: What is a resistance level?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.